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Population-level impact 
of human 
papillomavirus 
vaccination
We applaud the systematic review by 
Mélanie Drolet and colleagues1 that 
provides compelling evidence of the 
substantial impact of human 
papillomavirus (HPV) vaccination 
programmes, and we hope it will 
influence policy makers. 
However, the effect of vaccination in 
a population depends not only on the 
vaccine but also on the proportion of 
the population vaccinated. Hence, we 
would not expect the relative risk 
observed in different populations to 
be alike unless they had similar vaccine 
coverage. It is not enough to consider 
the uptake in the target population, as 
the coverage of the population 
studied also needs to be taken into 
account. If vaccination is only offered 
to 12–13-year-olds, there will be no 
observed effect in 15–19-year-olds 
within 2 years of vaccination. 
A simple correction could be used to 
estimate the effect of vaccination in 
vaccinated individuals (assuming that 
the underlying risk in vaccinated and 
unvaccinated individuals was the 
same and ignoring herd immunity). If 
we suppose the observed relative risk 
of disease (post-vaccination relative 
to pre-vaccination) is R and the 
vaccination coverage is C in the cohort 
under study, then a crude estimate of 
the efficacy (E) would be E = min(1, 
1 – [R – (1 – C)]/C), [A: we have edited 
this to house style, please check for 
accuracy] with the minimum imposed 
to prevent having greater than 100% 
efficacy. Meta-analysis of this quantity 
would provide a more easily 
interpretable effect measure. We 
hypothesise that the enormous 
heterogeneity reported for measures 
of efficacy would be greatly reduced 
by transforming to an efficacy scale.
We applied this transformation to 
data provided in the Article’s appendix 
(p 47, figure S1A) for changes in the 
prevalence of HPV infections girls 
aged 13–19 years. [A: please check OK 
as edited and confirm page number 
is correct] We were unable to 
reproduce Drolet and colleagues’ 
results precisely, but (before 
transformation) obtained an I² of 95% 
for 1–4 years [A: of follow-up?], 71% 
for 5–8 years, and 93% overall, and the 
heterogeneities were highly 
significant. Adjusting for vaccine 
coverage, the I² values were 42% for 
1–4 years, 0% for 5–8 years, and 33% 
overall, and none were significant. 
Further, the pooled vaccine efficacy 
was 92% for 1–4 years, 99% [A: Please 
provide these percentages to 1 
decimal place for consistency] for 
5–8 years, and 97·6% overall (with 
95% CI of at least 94·8%).[A: Please 
provide the confidence interval as a 
range. Or do you mean the upper 
95% confidence limit was at least 
94·8%?] 
These data show that [A: OK to 
add?] the impact of HPV vaccination 
on HPV type 16 or 18 [A: correct?] 
infections in girls has been substantial. 
After adjusting for vaccine coverage, 
vaccine efficacy is both homogeneous 
across populations and remarkable [A: 
remarkably high?].
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